Form D · Biotechnology

Novita Pharmaceuticals, Inc.

New York, NY · CIK 0001509360

Offering snapshot reported Oct 16, 2020 · SEC filing

Reported sold: $2.39M
Investors reported: 20
Minimum accepted: $0
First sale: Sep 7, 2019

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$560,000 → $2,390,000
Reported investors6 → 20

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 16, 2020	Amendment	$2,390,000	$1,830,000vs Oct 10, 2019	20	SEC filing
Oct 10, 2019	Initial	$560,000	No comparison	6	SEC filing
Apr 6, 2017	Amendment	$6,464,669	No comparison	30	SEC filing
Nov 2, 2016	Initial	Yet to sell	No comparison	0	SEC filing
Jan 4, 2011	Initial	$2,000,000	No comparison	24	SEC filing

Offering details

Securities: Debt, Option to acquire, Security to be acquired
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-350763

Source: Form D, filed Oct 16, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Xin Yun Huang	Director
Chenjian Li	Director
David Moy	Executive
Christy Y. Shue	Director, Executive
Jue Jillian Zhang	Director, Executive
Jonathan Jia Zhu	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1161 York Ave, Apt #8 C
New York, NY, 10065